Down -49.47% in 4 Weeks, Here's Why Myriad (MYGN) Looks Ripe for a Turnaround

Group 1 - Myriad Genetics (MYGN) has experienced a significant downtrend, with a stock decline of 49.5% over the past four weeks, but it is now in oversold territory, indicating a potential for a turnaround [1] - The Relative Strength Index (RSI) for MYGN is currently at 18.11, suggesting that the heavy selling pressure may be exhausting itself, which could lead to a reversal in the stock's trend [5] - Analysts have raised earnings estimates for MYGN by 11.1% over the last 30 days, indicating a strong consensus among sell-side analysts that could lead to price appreciation in the near term [7] Group 2 - MYGN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a near-term turnaround [8]